miRNA-21 as High Potential Prostate Cancer Biomarker in Prostate Cancer Patients in Indonesia

Gunawan, Regina R; Astuti, Indwiani; Danarto, H R

doi:10.31557/apjcp.2023.24.3.1095

Cited by 4 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gunawan и соавт. на выборке из 20 пациентов с РПЖ и 20 пациентов с ДГПЖ экспрессия miR-21-5p в образцах мочи различалась более чем в 12 раз между группами и продемонстрировала более высокие чувствительность и специфичность по сравнению с ПСА [48]. Эти данные в совокупности с результатами представленного исследования могут свидетельствовать о потенциальной диагностической значимости определения miR-21 у пациентов с РПЖ.…”

Section: диагностика и лечение опухолей мочеполовой системы рак предс...unclassified

Assessment of miR-21-5p, miR-451a, and miR-144-3p level in urine in differential diagnosis of localized prostate cancer

Dolotkazin,

Averinskaya,

Knyazev

et al. 2024

Onkourologiâ

View full text Add to dashboard Cite

Background. Limited sensitivity and specificity of existing prostate cancer (PCa) diagnosis methods drive the search for new markers. A number of studies has demonstrated the potential for measuring expression of certain microRNAs in urine.Aim. To evaluate the diagnostic potential of measuring microRNA expression in urine in PCa.Materials and methods. A collection of urine sediment samples from 19 patients with benign prostatic hyperplasia and 44 patients with PCa was analyzed. RNA was isolated using the miRNEasy Serum/Plasma Kit. 16 µL of RNA isolated from each sample were converted into cDNA, which served as a template for real-time polymerase chain reaction. For sequencing, microRNA libraries were prepared using MGIEasy Small RNA Library Prep Kit v.2.0. The formed DNA nanoballs were placed into an MGI DNBSEQ-G400 sequencer. Sequencing results were processed using IsoMiRmap. Differences in microRNA abundance were analyzed using DESeq2. For miRNA-21, high-throughput sequencing data were corroborated by the results of quantitative real-time polymerase chain reaction.Results. 1154 types of microRNA were identified, 11 were differentially represented in all comparison groups. The most significant differences in cell sediment between benign prostatic hyperplasia and PCa patients were recorded for miR-451a (area under the curve (AUC) 0.98). Additionally, the abundance levels of two microRNA isoforms were significantly different: hsa-miR-144-3p|-1 (AUC 0.96) and hsa-miR-21-5p|+4 (AUC 0.68).Сonclusion. This study confirms that altered expression of microRNAs miR-21, miR-451a and miR-144-3p is associated with PCa, can be detected in urine samples, and can also be a potential non-invasive diagnostic criterion.

show abstract

Section: диагностика и лечение опухолей мочеполовой системы рак предс...unclassified

Assessment of miR-21-5p, miR-451a, and miR-144-3p level in urine in differential diagnosis of localized prostate cancer

Dolotkazin,

Averinskaya,

Knyazev

et al. 2024

Onkourologiâ

View full text Add to dashboard Cite

show abstract

Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy

Prabhakaran,

Thamarai,

Sivasamy

et al. 2024

Epigenetics & Chromatin

View full text Add to dashboard Cite

Cancer has arisen from both genetic mutations and epigenetic changes, making epigenetics a crucial area of research for innovative cancer prevention and treatment strategies. This dual perspective has propelled epigenetics into the forefront of cancer research. This review highlights the important roles of DNA methylation, histone modifications and non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) and long non-coding RNAs, which are key regulators of cancer-related gene expression. It explores the potential of epigenetic-based therapies to revolutionize patient outcomes by selectively modulating specific epigenetic markers involved in tumorigenesis. The review examines promising epigenetic biomarkers for early cancer detection and prognosis. It also highlights recent progress in oligonucleotide-based therapies, including antisense oligonucleotides (ASOs) and antimiRs, to precisely modulate epigenetic processes. Furthermore, the concept of epigenetic editing is discussed, providing insight into the future role of precision medicine for cancer patients. The integration of nanomedicine into cancer therapy has been explored and offers innovative approaches to improve therapeutic efficacy. This comprehensive review of recent advances in epigenetic-based cancer therapy seeks to advance the field of precision oncology, ultimately culminating in improved patient outcomes in the fight against cancer.

show abstract

Urinary MicroRNA-21 for Prostate Cancer Detection Using a Silver Nanoparticle Sensor: A Promising Diagnostic Tool

Pang,

Chiou,

Lim

et al. 2024

Biosensors

View full text Add to dashboard Cite

In this study, we detected the expression levels of miR-21 in 38 clinical urine samples, obtained from 10 patients with PCa (with each sample obtained at three time points: before surgery, 1 month after surgery, and 3 months after surgery), 3 patients with benign prostatic hypertrophy (BPH), and 5 healthy subjects (as a control group). All of the samples were examined using a silver nanoparticle-based biosensor, and the sensitivity of the biosensor was simultaneously confirmed via qRT-PCR. The results were further analyzed together with clinical data such as PSA values and cancer stages. The sensitivity of the biosensor ranged up to 100 fM, and it presented a rather high selectivity rate. Our results indicated a significantly decreased expression level of miR-21 in the patient cases at 3 months post-surgery when compared with pre-surgery levels (p-value < 0.001). In addition, when distinguishing the differences in the expression level of miR-21 between healthy subjects and patients with PCa or BPH, both groups showed highly significant differences (p = 0.008 and p < 0.001, respectively). The results strongly suggest that the proposed miR-21 biosensor can be used as an auxiliary screening tool for the early detection of PCa and may effectively facilitate tracking of the progression of PCa, thus enabling more accurate healthcare decision making.

show abstract

miRNA-21 as High Potential Prostate Cancer Biomarker in Prostate Cancer Patients in Indonesia

Cited by 4 publications

References 17 publications

Assessment of miR-21-5p, miR-451a, and miR-144-3p level in urine in differential diagnosis of localized prostate cancer

Assessment of miR-21-5p, miR-451a, and miR-144-3p level in urine in differential diagnosis of localized prostate cancer

Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy

Urinary MicroRNA-21 for Prostate Cancer Detection Using a Silver Nanoparticle Sensor: A Promising Diagnostic Tool

Contact Info

Product

Resources

About